Sumitomo Pharma Co., Ltd.: Depressive Disorder trials

The registry lists 16 Depressive Disorder studies with Sumitomo Pharma Co., Ltd. as lead sponsor. 0 are open to participants now and 10 have results posted.

Phase 1 1Phase 2 2Phase 3 13(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Clinical Study of an Investigational Drug for the Treatment of Major Depressive Episode Associated With Bipolar I Disorder.TerminatedNCT05169710Phase 3Results posted
• A Clinical Study to Test the Effectiveness of an Investigational Drug to Treat People That Have Major Depressive Episodes When They Have Bipolar 1 DepressionCompletedNCT03543410Phase 2Results posted
• Lurasidone Pediatric Bipolar StudyCompletedNCT02046369Phase 3Results posted
• A Phase III Study of SM-13496 in Patients With Bipolar I Depression.CompletedNCT01986101Phase 3Results posted
• Major Depressive Disorder With Mixed Features - ExtensionCompletedNCT01423253Phase 3Results posted
• Major Depressive Disorder (MDD) With Mixed Features - Flexible DoseCompletedNCT01421134Phase 3Results posted
• Lurasidone HCI - A 6-week Phase 3 Study of Patients With Bipolar I DepressionCompletedNCT01284517Phase 3Results posted
• Lurasidone - A 24-week Extension Study of Patients With Bipolar I DepressionCompletedNCT00868959Phase 3Results posted
• Lurasidone - A 6-week Study of Patients With Bipolar I Depression (Monotherapy)CompletedNCT00868699Phase 3Results posted
• Lurasidone - A 6-week Study of Patients With Bipolar I Depression (Add-on)CompletedNCT00868452Phase 3Results posted
• A Study of Lurasidone Compared With Placebo for the Treatment of Bipolar I DepressionTerminatedNCT04383691Phase 3
• A Multiple Ascending Oral Dose Evaluation of the Safety, Tolerability, and Pharmacokinetics of DSP-1053 and Its Metabolites in Healthy Subjects and in Subjects With Major Depressive DisorderTerminatedNCT01774747Phase 1
• Major Depressive Disorder With Mixed FeaturesWithdrawnNCT01423240Phase 3
• A Safety, Efficacy and Tolerability Study of SEP-225289CompletedNCT00584974Phase 2
• A Study of Eszopiclone Co-administered With Venlafaxine in Subjects With Major Depressive Disorder and InsomniaCompletedNCT00435279Phase 3
• A Study of Eszopiclone in Subjects With Insomnia Related to Major Depressive DisorderCompletedNCT00368030Phase 3